{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:13:00Z","timestamp":1789776780787,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T00:00:00Z","timestamp":1501200000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s10875-017-0422-6","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T02:07:57Z","timestamp":1501207677000},"page":"548-558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Allogeneic Reduced-Intensity Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease: a Single-Center Prospective Trial"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0534-6759","authenticated-orcid":false,"given":"Mark","family":"Parta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kwatemaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narda","family":"Theobald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Hilligoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Kuhns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Zerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Malech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"issue":"11","key":"422_CR1","first-page":"1087","volume":"102","author":"A Ahlin","year":"2013","unstructured":"Ahlin A, Fugelang J, de Boer M, Ringden O, Fasth A, Winiarski J. Chronic granulomatous disease-haematopoietic stem cell transplantation versus conventional treatment. Acta Paediatr. 2013;102(11):1087\u201394.","journal-title":"Acta Paediatr"},{"issue":"3","key":"422_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10875-011-9513-y","volume":"31","author":"J Gozdzik","year":"2011","unstructured":"Gozdzik J, Pituch-Noworolska A, Skoczen S, Czogala W, Wedrychowicz A, Baran J, et al. Allogeneic haematopoietic stem cell transplantation as therapy for chronic granulomatous disease\u2014single centre experience. J Clin Immunol. 2011;31(3):332\u20137.","journal-title":"J Clin Immunol"},{"issue":"9","key":"422_CR3","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.bbmt.2012.02.002","volume":"18","author":"P Tewari","year":"2012","unstructured":"Tewari P, Martin PL, Mendizabal A, Parikh SH, Page KM, Driscoll TA, et al. Myeloablative transplantation using either cord blood or bone marrow leads to immune recovery, high long-term donor chimerism and excellent survival in chronic granulomatous disease. Biol Blood Marrow Transplant. 2012;18(9):1368\u201377.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"422_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1365-2141.2009.07614.x","volume":"145","author":"E Soncini","year":"2009","unstructured":"Soncini E, Slatter MA, Jones LB, Hughes S, Hodges S, Flood TJ, et al. Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. Br J Haematol. 2009;145(1):73\u201383.","journal-title":"Br J Haematol"},{"issue":"4","key":"422_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/petr.12471","volume":"19","author":"B Mehta","year":"2015","unstructured":"Mehta B, Mahadeo K, Kapoor N, Abdel-Azim H. Low-dose total-body irradiation and alemtuzumab-based reduced-intensity conditioning regimen results in durable engraftment and correction of clinical disease among children with chronic granulomatous disease. Pediatr Transplant. 2015;19(4):408\u201312.","journal-title":"Pediatr Transplant"},{"issue":"1","key":"422_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaci.2011.10.005","volume":"129","author":"CA Martinez","year":"2012","unstructured":"Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012;129(1):176\u201383.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"422_CR7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","volume":"132","author":"T Cole","year":"2013","unstructured":"Cole T, Pearce MS, Cant AJ, Cale CM, Goldblatt D, Gennery AR. Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;132(5):1150\u20135.","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"422_CR8","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.1182\/blood-2002-02-0583","volume":"100","author":"RA Seger","year":"2002","unstructured":"Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985\u20132000. Blood. 2002;100(13):4344\u201350.","journal-title":"Blood"},{"issue":"9915","key":"422_CR9","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","volume":"383","author":"T Gungor","year":"2014","unstructured":"Gungor T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436\u201348.","journal-title":"Lancet"},{"issue":"12","key":"422_CR10","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1056\/NEJM200103223441203","volume":"344","author":"ME Horwitz","year":"2001","unstructured":"Horwitz ME, Barrett AJ, Brown MR, Carter CS, Childs R, Gallin JI, et al. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344(12):881\u20138.","journal-title":"N Engl J Med"},{"issue":"27","key":"422_CR11","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","volume":"363","author":"DB Kuhns","year":"2010","unstructured":"Kuhns DB, Alvord WG, Heller T, Feld JJ, Pike KM, Marciano BE, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med. 2010;363(27):2600\u201310.","journal-title":"N Engl J Med"},{"issue":"1","key":"422_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00280-007-0455-2","volume":"61","author":"G Vassal","year":"2008","unstructured":"Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61(1):113\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"422_CR13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1399-3046.2011.01529.x","volume":"15","author":"R Malar","year":"2011","unstructured":"Malar R, Sjoo F, Rentsch K, Hassan M, Gungor T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant. 2011;15(6):580\u20138.","journal-title":"Pediatr Transplant"},{"issue":"3","key":"422_CR14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/blood-2016-03-704015","volume":"128","author":"B Morillo-Gutierrez","year":"2016","unstructured":"Morillo-Gutierrez B, Beier R, Rao K, Burroughs L, Schulz A, Ewins AM, et al. Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience. Blood. 2016;128(3):440\u20138.","journal-title":"Blood"},{"issue":"10","key":"422_CR15","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.bbmt.2011.07.005","volume":"17","author":"S Bhatia","year":"2011","unstructured":"Bhatia S, Davies SM, Scott Baker K, Pulsipher MA, Hansen JA. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: etiology and pathogenesis of late effects after HCT performed in childhood\u2014methodologic challenges. Biol Blood Marrow Transplant. 2011;17(10):1428\u201335.","journal-title":"Biol Blood Marrow Transplant."},{"issue":"8","key":"422_CR16","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1097\/00007890-200204270-00016","volume":"73","author":"HD Ottinger","year":"2002","unstructured":"Ottinger HD, Rebmann V, Pfeiffer KA, Beelen DW, Kremens B, Runde V, et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation. 2002;73(8):1280\u20135.","journal-title":"Transplantation"},{"issue":"1","key":"422_CR17","doi-asserted-by":"publisher","first-page":"E68","DOI":"10.1111\/j.1399-0012.2010.01324.x","volume":"25","author":"M Remberger","year":"2011","unstructured":"Remberger M, Mattsson J, Olsson R, Ringden O. Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. Clin Transpl. 2011;25(1):E68\u201376.","journal-title":"Clin Transpl"},{"issue":"2","key":"422_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pbc.25225","volume":"62","author":"B Oshrine","year":"2015","unstructured":"Oshrine B, Morsheimer M, Heimall J, Bunin N. Reduced-intensity conditioning for hematopoietic cell transplantation of chronic granulomatous disease. Pediatr Blood Cancer. 2015;62(2):359\u201361.","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"422_CR19","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","volume":"116","author":"R Chakraverty","year":"2010","unstructured":"Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010;116(16):3080\u20138.","journal-title":"Blood"},{"issue":"11","key":"422_CR20","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.bbmt.2013.09.001","volume":"19","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Kim MO, Liu C, Bellman D, Hart L, Grimley M, et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Biol Blood Marrow Transplant. 2013;19(11):1625\u201331.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"422_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/bmt.2013.207","volume":"49","author":"TG Ketterl","year":"2014","unstructured":"Ketterl TG, Flesher M, Shanley R, Miller W. Early CD3+\/CD15+ peripheral blood leukocyte chimerism patterns correlate with long-term engraftment in non-malignant hematopoietic SCT. Bone Marrow Transplant. 2014;49(4):572\u20135.","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"422_CR22","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/leu.2011.244","volume":"26","author":"S Breuer","year":"2012","unstructured":"Breuer S, Preuner S, Fritsch G, Daxberger H, Koenig M, Poetschger U, et al. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation. Leukemia. 2012;26(3):509\u201319.","journal-title":"Leukemia"},{"issue":"12","key":"422_CR23","doi-asserted-by":"publisher","first-page":"6649","DOI":"10.4049\/jimmunol.0903729","volume":"184","author":"D Zecher","year":"2010","unstructured":"Zecher D, Li Q, Oberbarnscheidt MH, Demetris AJ, Shlomchik WD, Rothstein DM, et al. NK cells delay allograft rejection in lymphopenic hosts by downregulating the homeostatic proliferation of CD8+ T cells. J Immunol. 2010;184(12):6649\u201357.","journal-title":"J Immunol"},{"issue":"3","key":"422_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood-2007-10-120089","volume":"112","author":"S Laffont","year":"2008","unstructured":"Laffont S, Seillet C, Ortaldo J, Coudert JD, Guery JC. Natural killer cells recruited into lymph nodes inhibit alloreactive T-cell activation through perforin-mediated killing of donor allogeneic dendritic cells. Blood. 2008;112(3):661\u201371.","journal-title":"Blood"},{"issue":"12","key":"422_CR25","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.4049\/jimmunol.0902598","volume":"184","author":"M Noval Rivas","year":"2010","unstructured":"Noval Rivas M, Hazzan M, Weatherly K, Gaudray F, Salmon I, Braun MY. NK cell regulation of CD4 T cell-mediated graft-versus-host disease. J Immunol. 2010;184(12):6790\u20138.","journal-title":"J Immunol"},{"issue":"11","key":"422_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1097\/01.tp.0000185299.72295.90","volume":"80","author":"JD Powell","year":"2005","unstructured":"Powell JD, Fitzhugh C, Kang EM, Hsieh M, Schwartz RH, Tisdale JF. Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism. Transplantation. 2005;80(11):1541\u20135.","journal-title":"Transplantation"},{"issue":"24","key":"422_CR27","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","volume":"361","author":"MM Hsieh","year":"2009","unstructured":"Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309\u201317.","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-017-0422-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0422-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-017-0422-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T20:56:28Z","timestamp":1719348988000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-017-0422-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s10875-017-0422-6","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"assertion":[{"value":"20 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Informed consent was obtained from all individual participants included in the study under IRB approved NIH Protocol No. 07-I-0075.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}